
High levels of lipoprotein(a) – assessment and treatment

CLINICAL REVIEW

TONE SVILAAS

tosvil@ous-hf.no

Lipid Clinic

and

Norwegian National Advisory Unit on Familial Hypercholesterolaemia
Department of Endocrinology, Morbid Obesity and Preventive Medicine
Oslo University Hospital, Aker Hospital

Author contribution: idea, literature search and first draft, design,
revision and approval of the manuscript.

Tone Svilaas PhD, specialist in internal medicine and senior consultant.
The author has completed the ICMJE form and declares no conflicts of
interest.

TOR OLE KLEMSDAL

Preventive Cardiology

Department of Endocrinology, Morbid Obesity and Preventive Medicine
Oslo University Hospital, Aker Hospital

Author contribution: expert input, and design, revision and approval of
the manuscript.

Tor Ole Klemsdal PhD, specialist in internal medicine and cardiology,
senior consultant and head of section.

The author has completed the ICMJE form and declares the following
conflicts of interest: He has received lecture fees from AstraZeneca,
BMS, Pfizer and Sanofi-Aventis (manufacturer of the PCSK9 inhibitor
alirocumab). He has received fees from the Norwegian Directorate of
Health as an expert involved in the development of national guidelines.

MARTIN PRØVEN BOGSRUD

Unit for Cardiac and Cardiovascular Genetics

Department of Medical Genetics

Oslo University Hospital, Ullevål Hospital

Author contribution: expert input, and design, revision and approval of the manuscript.

Martin Prøven Bogsrud PhD, doctor, researcher and head of unit.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received fees for lecturing and participation in expert group meetings from Amgen (manufacturer of the PCSK9 inhibitor evolocumab) and Sanofi (manufacturer of the PCSK9 inhibitor alirocumab). He is an advisor for the Norwegian patient organisation for people with familial hypercholesterolemia (FH Norge) and head of the reference group for the Norwegian national advisory unit on familial hypercholesterolaemia.

ASGEIR GRÆSDAL

Vestfold Centre for Internal Medicine, Sandefjord

Author contribution: expert input, and design, revision and approval of the manuscript.

Asgeir Græsdal, specialist in internal medicine and specialist private practitioner.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received fees for meetings with general practitioners from Novartis (manufacturer of the antisense oligonucleotide pelacarsen), Sanofi (manufacturer of the PCSK9 inhibitor alirocumab) and Amgen (manufacturer of the PCSK9 inhibitor evolocumab).

ELISABETH KLEIVHAUG VESTERBEKKMO

Clinic of Cardiology

St Olav's Hospital, Trondheim University Hospital
and

Department of Circulation and Medical Imaging

Faculty of Medicine and Health Sciences

Norwegian University of Science and Technology, Trondheim

Author contribution: expert input, and design, revision and approval of the manuscript.

Elisabeth Kleivhaug Vesterbekkmo, specialist in internal medicine and cardiology, senior consultant and doctoral research fellow.

The author has completed the ICMJE form and declares the following conflicts of interest: She has received fees for participation in expert group meetings and for lecturing from Amgen (manufacturer of the PCSK9 inhibitor evolocumab), Novartis (manufacturer of the antisense oligonucleotide pelacarsen) and Sanofi (manufacturer of the PCSK9 inhibitor alirocumab). She is an advisor for the Norwegian working group on preventive cardiology (AG Preventiv), the Norwegian Society of

Cardiology (NCS), the Norwegian Internal Medicine Association, the Norwegian national advisory unit on exercise training as medicine and the Norwegian national advisory unit on familial hypercholesterolaemia.

EMIL ANDREAS ASPRUSTEN

Lipid Clinic

Department of Endocrinology, Morbid Obesity and Preventive Medicine
Oslo University Hospital, Aker Hospital

Author contribution: design, revision and approval of the manuscript.

Emil Andreas Asprusten, specialist in internal medicine and senior consultant.

The author has completed the **ICMJE form** and declares the following conflicts of interest: He has participated in expert group meetings for Sanofi (manufacturer of the PCSK9 inhibitor alirocumab) and Novartis (manufacturer of the antisense oligonucleotide pelacarsen).

GISLE LANGSLET

Lipid Clinic

and

Norwegian National Advisory Unit on Familial Hypercholesterolaemia
Department of Endocrinology, Morbid Obesity and Preventive Medicine
Oslo University Hospital, Aker Hospital

Author contribution: expert input, literature search, and design, revision and approval of the manuscript.

Gisle Langslet PhD, senior consultant.

The author has completed the **ICMJE form** and declares the following conflicts of interest: He has received fees for lecturing and participation in expert group meetings from Amgen (manufacturer of the PCSK9 inhibitor evolocumab), Sanofi (manufacturer of the PCSK9 inhibitor alirocumab) and Boehringer Ingelheim.

KJETIL RETTERSTØL

Lipid Clinic

Department of Endocrinology, Morbid Obesity and Preventive Medicine
Oslo University Hospital, Aker Hospital

and

Department of Nutrition
Institute of Basic Medical Sciences
University of Oslo

Author contribution: idea, expert input, and preparation, revision and approval of the manuscript.

Kjetil Retterstøl PhD, specialist in medical biochemistry, senior consultant and professor.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received lecture fees from Akcea, Amgen (manufacturer of the PCSK9 inhibitor evolocumab), Bayer, Chiesi, MSD, Novartis (manufacturer of the antisense oligonucleotide pelacarsen), Sanofi (manufacturer of the PCSK9 inhibitor alirocumab), Sunovion and Takeda, as well as hourly fees from MedXplore and the Norwegian Directorate of Health..

Approximately 5 % of the population have highly elevated levels of lipoprotein(a) (Lp(a)), which is a genetically determined risk factor for cardiovascular disease. Measuring lipoprotein(a) can improve cardiovascular risk stratification and have consequences for preventive measures. Treatment is targeted at reducing modifiable cardiovascular risk factors, but Lp(a)-lowering drugs are being trialled. This article reviews the management of lipoprotein(a) in clinical practice.

Lipoprotein(a), abbreviated as Lp(a) and often referred to as *lipoprotein little a*, was first identified in 1963 by the Norwegian Kåre Berg (1). In recent years, lipoprotein(a) has gained increased attention as a risk factor for cardiovascular disease after several studies demonstrated that cardiovascular risk increases proportionally with increasing levels of lipoprotein(a) (2–9). Treatment for selective reduction of plasma lipoprotein(a) is currently being trialled (10). Lipid clinics in Norway are experiencing ever-increasing volumes of enquiries related to lipoprotein(a). According to reimbursement data from the Norwegian Control and Payment of Health Reimbursements (KUHR) database, approximately 50,000 measurements of lipoprotein(a) were performed in 2021 (Vegard Håvik, personal communication).

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) published guidelines for lipoprotein(a) in 2019 (11). This article aims to give a short review of lipoprotein(a) as a cardiovascular risk factor and to outline strategies for the assessment and treatment of high lipoprotein(a) levels, adapted to the situation in Norway. The article is based on a discretionary selection of the relevant literature, Norwegian and international guidelines, the authors' own clinical experience and a specialist procedure.

Pathophysiology

Lipoprotein(a) is a low-density lipoprotein (LDL) particle with an added apolipoprotein, apolipoprotein(a) (abbreviated as apo(a)). Apolipoprotein(a) contains loop structures called kringles. Apolipoprotein(a) size is determined

by the number of copies of kringle IV type 2 (KIV type 2) and is inversely correlated with levels of Lp(a) (Figure 1). The number of copies is determined by variations in the gene encoding apolipoprotein(a) (the LPA gene).




Figure 1 The structure of lipoprotein(a). Lipoprotein(a) is an LDL particle attached to apolipoprotein(a) (apo(a)). Apolipoprotein(a) consists of loop-like structures called *kringles*. Apolipoprotein(a) size is determined by the number of copies of *kringle IV type 2* (KIV type 2) and is inversely correlated with levels of lipoprotein(a). The figure shows eight copies of KIV type 2. Apolipoprotein(a) can bind oxidised phospholipids. ApoB = apolipoprotein B. Illustration: Illumedic

Lipoprotein(a) is thought to cause atherosclerosis as a result of both its cholesterol-rich LDL particle and apolipoprotein(a). The LDL particle can penetrate through the endothelial wall and cause lipid deposition, and apolipoprotein(a) can bind oxidised phospholipids and induce an inflammatory response, which in turn can lead to atherosclerosis and aortic valve calcification (7). Apolipoprotein(a) structurally resembles plasminogen and, in theory, may influence coagulation (12).

Incidence

Levels of lipoprotein(a) are primarily determined by genetic factors, remain very stable throughout life and are relatively unaffected by dietary habits and lifestyle. The distribution of Lp(a) levels in the population is skewed: about 20 % have elevated levels exceeding approximately 125 nmol/L (approximately

500 mg/L) (2, 3, 11, 13). The population data are mainly based on European populations. Individuals of African and Asian descent are known to have higher and lower Lp(a) levels respectively (9, 14). However, no difference in increased cardiovascular risk for an equal Lp(a) increment was found in various ethnic groups (14). No relevant differences have been detected between sexes in thresholds or Lp(a)-associated risk (3).

Diagnostic testing

Elevated levels of lipoprotein(a) do not themselves cause clinical symptoms. Isolated elevated Lp(a) levels are rarely treated alone. Therefore, national expert guidelines for cardiovascular disease prevention advise against routine measurement of lipoprotein(a) (15). European guidelines from 2019 allow for measurement of lipoprotein(a), even without other risk factors, in order to identify individuals with exceptionally high levels (11). This is partly based on the results of a large mendelian randomisation analysis which demonstrated that very high levels (above 430 nmol/L) can result in a three/four-fold increase in the risk of coronary heart disease, a risk similar to familial hypercholesterolaemia (8).

Measurement of Lp(a) can improve risk stratification and have consequences for future diagnostic assessment and optimisation of preventive treatment. At Oslo University Hospital, we have developed a specialist procedure with recommendations for the assessment of Lp(a) levels (16). Measuring Lp(a) levels should be considered once in a lifetime as part of the lipid profile in cardiovascular risk assessment (2–4, 8, 14, 17) and particularly in the conditions described in Box 1 (7, 13).

Box 1 Conditions in which lipoprotein(a) may be a particular risk-modulating factor. Based on Nordestgaard et al. (7) and Wilson et al. (13).

Intermediate cardiovascular risk where additional information about Lp(a) levels takes the patient over the intervention threshold. Age-dependent intervention threshold in NORRISK 2 (45–54 years: > 5 %, 55–64 years: > 10 %, 65–74 years: > 15 %) (20).

Family history of premature cardiovascular disease

Severe elevation of LDL cholesterol or familial hypercholesterolaemia

Premature cardiovascular disease

Recurrent cardiovascular disease with control of other cardiovascular risk factors

Blood sample analysis

Lipoprotein(a) is measured in nmol/L or mg/L. There are inaccuracies in a conversion factor between the units for reasons that include the analysis method and size of apolipoprotein(a) (18). The conversion factor from mg/L to nmol/L is approximately 0.24. Conversions for some Lp(a) values are given as a guide in Table 1. Fasting prior to measurement is not required.

Table 1

Population percentiles and cardiovascular risk for various Lp(a) categories, with recommendations for intervention. The conversion factor from mg/L to nmol/L is approximately 0.24. The multiplication factor estimates the increased risk associated with the Lp(a) category in addition to the baseline risk from NORRISK 2 (15).

Degree of Lp(a) elevation	Lp(a) levels (nmol/L)	Lp(a) levels (mg/L)	Percentile of the population	Multiplication factor for cardiovascular risk	Consideration of intervention ¹
Mild	75–125	300–500	75		--
Moderate	125–250	500–1,000	80–95		1.5 Yes, for patients with comorbid conditions ²
High	250–400	1,000–1,800	95–99		1.5 ³ Yes, for patients with comorbid conditions
Very high	> 400	> 1,800	> 99		4 Yes, even without comorbid conditions

¹Intervention = drug treatment alongside lifestyle advice.

²Comorbid conditions as described in Box 1.

³Risk increases gradually between the categories (2, 3, 6).

⁴Very high Lp(a) levels can result in as much as a three/four-fold increase in cardiovascular risk, which may itself be grounds for intervention (8, 14, 21).

Lipoprotein(a) contains LDL cholesterol in varying amounts. Therefore, high Lp(a) levels can increase levels of LDL cholesterol in the blood. Statin treatment does not reduce lipoprotein(a) levels and, therefore, will not reduce LDL cholesterol bound to lipoprotein(a) either. This can manifest as resistance to statin treatment (19).

Cardiovascular risk and consideration of intervention

Norwegian laboratories usually specify Lp(a) elevation when levels exceed 75 nmol/L and 300 mg/L. In line with international consensus statements, we use a threshold for increased cardiovascular risk at Lp(a) levels of approximately 125 nmol/L (approximately 500 mg/L) (3, 7, 13). There is no definite increased risk at levels below this threshold. Based on the available literature, Table 1 shows Lp(a) levels according to clinically relevant cardiovascular risk (2, 3, 6).

For an individual assessment of risk associated with elevated Lp(a) levels in primary prevention, the Norwegian national expert guidelines for cardiovascular disease prevention recommend calculating cardiovascular risk using the NORRISK 2 calculator (20) and then revising the estimate upwards by a factor of 1.5 (15), which is the multiplication factor indicated in Table 1. From high to very high Lp(a) levels, this factor is probably on the low side – a two/three-fold increase in the risk of myocardial infarction and aortic valve stenosis has been reported at levels above 250 nmol/L (approximately 1,000 mg/L) (5, 14), and levels above 400 nmol/L (approximately 1800 mg/L) can result in as much as a three/four-fold increase in the risk of ischaemic heart disease (8, 14, 21). Interpretation of borderline levels requires clinical judgement and, in case of uncertainty, referral to the specialist health service. No evidence is available for the use of Lp(a) levels as a risk modulator above the age of 75 years, but the significance is thought to be largely the same.

Intervention

Reduction of total cardiovascular risk

No specific Lp(a)-lowering treatment is currently available (see below). The treatment of individuals with elevated Lp(a) levels is targeted at the other cardiovascular risk factors. It has been demonstrated that patients with a low total risk have a lower cardiovascular risk despite excessively high Lp(a) levels (22).

Treatment follows the Norwegian national expert guidelines for cardiovascular disease prevention (15). This involves focus on dietary and lifestyle measures and, if necessary, treatment of hypertension and diabetes. Most patients will require cholesterol-lowering treatment as well.

The treatment target for LDL cholesterol is assessed on an individual basis. In primary prophylaxis, no specific treatment target has been set for LDL cholesterol in patients with high Lp(a) levels, but the target will often be to reduce LDL cholesterol levels to below 2.5–3 mmol/L in patients at increased risk (11, 13, 20, 22, 23). In patients with conditions entailing a high to very high cardiovascular risk, the target is based on the LDL target given for that condition (for example the LDL target for diabetes, familial hypercholesterolaemia or atherosclerotic disease) (15, 17, 23).

Reduction of lipoprotein(a)

It is likely that levels of lipoprotein(a) will need to be considerably reduced to achieve an effect on cardiovascular events. Theoretical calculations estimate that a reduction in Lp(a) levels of around 100 nmol/L produces almost the same risk reduction as a reduction in LDL cholesterol of 1 mmol/L (8, 17). Post-hoc analyses of studies with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in secondary prevention report a reduction in Lp(a) levels of approximately 25 %, but a reduction in cardiovascular events has not been established (24). Selective Lp(a) reduction as primary prevention has not yet been studied.

Lipoprotein apheresis is a dialysis-like treatment that reduces levels of lipoprotein(a) and LDL cholesterol by around 30 % on average. Observational studies have shown a clear reduction in cardiovascular events with lipoprotein apheresis, but it is unclear how much of the effect is due to reduction of lipoprotein(a) and LDL cholesterol respectively (25). The treatment is time-consuming and expensive, but can be considered in cases of very high levels of lipoprotein(a) and recurrent cardiovascular disease despite good control of LDL cholesterol. In Norway, very few patients are treated with lipoprotein apheresis for high Lp(a) levels.

Selective reduction of lipoprotein(a) with drugs such as an apo(a) antisense oligonucleotide is being trialled. This treatment has resulted in a dose-dependent reduction in lipoprotein(a) of 35–80 %, (26). Studies into the effect of Lp(a) reduction on cardiovascular events are expected in 2024 (10). Lp(a)-lowering treatment may then become appropriate adjuvant treatment.

Follow-up

Most Lp(a) measurements will be performed by general practitioners as part of a standard cardiovascular risk assessment (NORRISK 2). Patients are followed up in line with the Norwegian national expert guidelines for cardiovascular disease prevention (15). Follow-up of patients with very high lipoprotein(a) levels in the specialist health service may be indicated.

In the event of possible cardiovascular symptoms or suspected aortic valve disease, the patient should be referred for assessment by a cardiologist or other relevant vascular evaluation.

Children and adolescents

There is limited information about recommendations regarding Lp(a) measurement in children and adolescents below the age of 18 years. Measurements can be performed in the specialist health service when children are considered for lipid-lowering treatment, such as in cases of familial hypercholesterolaemia (13, 27).

Screening of relatives

Due to the heritability of Lp(a), family members of an individual with elevated lipoprotein(a) may also have high levels. However, the significance of the levels and recommended treatment depend on the individual's other risk factors. A risk assessment, including Lp(a) measurement, is recommended in cases of a first-degree relative having very high Lp(a) levels and premature heart disease themselves or in the immediate family, which is presumed to be due to lipoprotein(a) (13, 16). This also applies to children aged 8 - 10 years, and in these cases the assessment will be primarily a specialist service (27).

Conclusion

Lipoprotein(a) is a fatty substance, and blood levels are genetically determined. High levels are associated with an increased risk of cardiovascular disease. Information about lipoprotein(a) can improve cardiovascular risk stratification and be of relevance for intensification of preventive treatment.

After the manuscript for this article was accepted, a new consensus statement was published in 2022 by the European Atherosclerosis Society (EAS) with a more proactive approach as regards the assessment and treatment of high Lp(a) levels (). Discussions are ongoing about adapting this statement to the situation in Norway. In European and other international guidelines, there is agreement that Lp(a) levels should be interpreted and treated in relation to other cardiovascular risk factors. This implies that lipoprotein(a) should not be measured in isolation without undertaking an assessment of total cardiovascular risk or other comorbid conditions as described in Box 1.

The article has been peer-reviewed.

REFERENCES

1. Berg K. A New serum type system in man – the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–82. [PubMed][CrossRef]
2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331–9. [PubMed][CrossRef]
3. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412–23. [PubMed][CrossRef]
4. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518–28. [PubMed][CrossRef]

5. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. *J Am Coll Cardiol* 2014; 63: 470–7. [PubMed][CrossRef]
6. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. *Eur Heart J* 2019; 40: 2760–70. [PubMed][CrossRef]
7. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010; 31: 2844–53. [PubMed][CrossRef]
8. Burgess S, Ference BA, Staley JR et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. *JAMA Cardiol* 2018; 3: 619–27. [PubMed][CrossRef]
9. Paré G, Çaku A, McQueen M et al. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. *Circulation* 2019; 139: 1472–82. [PubMed][CrossRef]
10. HORIZON. Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON). <https://www.centerwatch.com/clinical-trials/listings/234256/assessing-the-impact-of-lipoprotein-a-lowering-with-pelacarsen-tqj230-on-major-cardiovascular-events-in-patients-with-cvd/> Accessed 12.7.2022.
11. Mach F, Baigent C, Catapano AL et al. ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2019; 0: 1–78.
12. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res* 2016; 57: 1953–75. [PubMed][CrossRef]
13. Wilson DP, Jacobson TA, Jones PH et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol* 2019; 13: 374–92. [PubMed][CrossRef]
14. Patel AP, Wang M, Pirruccello JP et al. Lipoprotein(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights from a Large National Biobank. *Arterioscler Thromb Vasc Biol* 2021; 41: 465–74. [PubMed]
15. Helsedirektoratet. Nasjonal faglig retningslinje for forebygging av hjerte-og karsykdom. <https://www.helsedirektoratet.no/retningslinjer/forebygging-av-hjerte-og-karsykdom> Accessed 25.11.2022.
16. Oslo universitetssykehus. E-håndbok. Nivå 2 prosedyre Lipoprotein(a) - utredning og behandling. <https://ehandboken.ous-hf.no/> Accessed 1.11.2021.

17. Madsen CM, Kamstrup PR, Langsted A et al. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. *Arterioscler Thromb Vasc Biol* 2020; 40: 255–66. [PubMed][CrossRef]
18. Guadagno PA, Summers Bellin EG, Harris WS et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. *Clin Chim Acta* 2015; 439: 219–24. [PubMed][CrossRef]
19. Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. *Curr Opin Lipidol* 2015; 26: 169–78. [PubMed][CrossRef]
20. Helsedirektoratet. NORRISK 2. Kalkulator for hjerterisiko. <https://hjerterisiko.helsedirektoratet.no/> Accessed 25.11.2022.
21. Kamstrup PR. Lipoprotein(a) and cardiovascular disease. *Clin Chem* 2021; 67: 154–66. [PubMed][CrossRef]
22. Verbeek R, Hoogeveen RM, Langsted A et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. *Eur Heart J* 2018; 39: 2589–96. [PubMed][CrossRef]
23. Retterstøl K, Munkhaugen J, Ingul CB et al. Lavere behandlingsmål for LDL-kolesterol bør innføres. *Tidsskr Nor Legeforen* 2021; 141: 122–4. [PubMed][CrossRef]
24. O'Donoghue ML, Fazio S, Giugliano RP et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. *Circulation* 2019; 139: 1483–92. [PubMed][CrossRef]
25. Leebmann J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. *Circulation* 2013; 128: 2567–76. [PubMed][CrossRef]
26. Tsimikas S, Karwowska-Prokopczuk E, Gouni-Berthold I et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med* 2020; 382: 244–55. [PubMed][CrossRef]
27. Kohn B, Ashraf AP, Wilson DP. Should Lipoprotein(a) be Measured in Youth? *J Pediatr* 2021; 228: 285–9. [PubMed][CrossRef]
28. Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J* 2022; 43: 3925–46. [PubMed][CrossRef]

Publisert: 12 January 2023. Tidsskr Nor Legeforen. DOI: 10.4045/tidsskr.21.0800
Received 12.11.2021, first revision submitted 5.5.2022, accepted 12.7.2022.
Published under open access CC BY-ND. Downloaded from tidsskriftet.no 14 June 2026.